174 related articles for article (PubMed ID: 20186168)
1. Nosokomycins, new antibiotics discovered in an in vivo-mimic infection model using silkworm larvae. I: Fermentation, isolation and biological properties.
Uchida R; Iwatsuki M; Kim YP; Ohte S; Omura S; Tomoda H
J Antibiot (Tokyo); 2010 Apr; 63(4):151-5. PubMed ID: 20186168
[TBL] [Abstract][Full Text] [Related]
2. Nosokomycins, new antibiotics discovered in an in vivo-mimic infection model using silkworm larvae. II: Structure elucidation.
Uchida R; Iwatsuki M; Kim YP; Omura S; Tomoda H
J Antibiot (Tokyo); 2010 Apr; 63(4):157-63. PubMed ID: 20203703
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo anti-MRSA activities of nosokomycins.
Uchida R; Hanaki H; Matsui H; Hamamoto H; Sekimizu K; Iwatsuki M; Kim YP; Tomoda H
Drug Discov Ther; 2014 Dec; 8(6):249-54. PubMed ID: 25639304
[TBL] [Abstract][Full Text] [Related]
4. The synergistic antibacterial activity of 1-acetyl-beta-carboline and beta-lactams against methicillin-resistant Staphylococcus aureus (MRSA).
Shin HJ; Lee HS; Lee DS
J Microbiol Biotechnol; 2010 Mar; 20(3):501-5. PubMed ID: 20372018
[TBL] [Abstract][Full Text] [Related]
5. Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144. I. Taxonomy, fermentation, isolation and structural elucidation.
Fukumoto A; Kim YP; Matsumoto A; Takahashi Y; Shiomi K; Tomoda H; Omura S
J Antibiot (Tokyo); 2008 Jan; 61(1):1-6. PubMed ID: 18305352
[TBL] [Abstract][Full Text] [Related]
6. NW-G01, a novel cyclic hexadepsipeptide antibiotic, produced by Streptomyces alboflavus 313: I. Taxonomy, fermentation, isolation, physicochemical properties and antibacterial activities.
Guo Z; Shen L; Ji Z; Zhang J; Huang L; Wu W
J Antibiot (Tokyo); 2009 Apr; 62(4):201-5. PubMed ID: 19265870
[TBL] [Abstract][Full Text] [Related]
7. Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144. II. Biological activities.
Fukumoto A; Kim YP; Hanaki H; Shiomi K; Tomoda H; Omura S
J Antibiot (Tokyo); 2008 Jan; 61(1):7-10. PubMed ID: 18305353
[TBL] [Abstract][Full Text] [Related]
8. Discovery of nosokophic acid, a predicted intermediate of moenomycins, from nosokomycin-producing Streptomyces sp. K04-0144.
Koyama N; Tokura Y; Takahashi Y; Tomoda H
Bioorg Med Chem Lett; 2013 Feb; 23(3):860-3. PubMed ID: 23265883
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterisation of a Streptomyces sp. isolate exhibiting activity against methicillin-resistant Staphylococcus aureus.
Higginbotham SJ; Murphy CD
Microbiol Res; 2010; 165(1):82-6. PubMed ID: 19231147
[TBL] [Abstract][Full Text] [Related]
10. Neopyrrolomycins with broad spectrum antibacterial activity.
Hopp DC; Rhea J; Jacobsen D; Romari K; Smith C; Rabenstein J; Irigoyen M; Clarke M; Francis L; Luche M; Carr GJ; Mocek U
J Nat Prod; 2009 Feb; 72(2):276-9. PubMed ID: 19191549
[TBL] [Abstract][Full Text] [Related]
11. Two piperazic acid-containing cyclic hexapeptides from Streptomyces alboflavus 313.
Wei S; Fan L; Wu W; Ji Z
Amino Acids; 2012 Nov; 43(5):2191-8. PubMed ID: 22543750
[TBL] [Abstract][Full Text] [Related]
12. Viridicatumtoxin B, a new anti-MRSA agent from Penicillium sp. FR11.
Zheng CJ; Yu HE; Kim EH; Kim WG
J Antibiot (Tokyo); 2008 Oct; 61(10):633-7. PubMed ID: 19168978
[TBL] [Abstract][Full Text] [Related]
13. New Approaches to Drug Discovery for Combating MRSA.
Tomoda H
Chem Pharm Bull (Tokyo); 2016; 64(2):104-11. PubMed ID: 26833438
[TBL] [Abstract][Full Text] [Related]
14. Oridamycins A and B, anti-Saprolegnia parasitica indolosesquiterpenes isolated from Streptomyces sp. KS84.
Takada K; Kajiwara H; Imamura N
J Nat Prod; 2010 Apr; 73(4):698-701. PubMed ID: 20369841
[TBL] [Abstract][Full Text] [Related]
15. Selection of Streptomyces isolates from Turkish karstic caves against antibiotic resistant microorganisms.
Yücel S; Yamaç M
Pak J Pharm Sci; 2010 Jan; 23(1):1-6. PubMed ID: 20067859
[TBL] [Abstract][Full Text] [Related]
16. Guadinomines, Type III secretion system inhibitors, produced by Streptomyces sp. K01-0509. I: taxonomy, fermentation, isolation and biological properties.
Iwatsuki M; Uchida R; Yoshijima H; Ui H; Shiomi K; Matsumoto A; Takahashi Y; Abe A; Tomoda H; Omura S
J Antibiot (Tokyo); 2008 Apr; 61(4):222-9. PubMed ID: 18503201
[TBL] [Abstract][Full Text] [Related]
17. Silkworm larvae as an animal model of bacterial infection pathogenic to humans.
Kaito C; Akimitsu N; Watanabe H; Sekimizu K
Microb Pathog; 2002 Apr; 32(4):183-90. PubMed ID: 12079408
[TBL] [Abstract][Full Text] [Related]
18. Isolation and characterization of two novel antibacterial cyclic hexapeptides from Streptomyces alboflavus 313.
Ji Z; Qiao G; Wei S; Fan L; Wu W
Chem Biodivers; 2012 Aug; 9(8):1567-78. PubMed ID: 22899617
[TBL] [Abstract][Full Text] [Related]
19. [Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci].
Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López F; Gómez M;
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):13-6. PubMed ID: 19406529
[TBL] [Abstract][Full Text] [Related]
20. Naphthacemycins, novel circumventors of β-lactam resistance in MRSA, produced by Streptomyces sp. KB-3346-5. I. The taxonomy of the producing strain, and the fermentation, isolation and antibacterial activities.
Fukumoto A; Kim YP; Matsumoto A; Takahashi Y; Suzuki M; Onodera H; Tomoda H; Matsui H; Hanaki H; Iwatsuki M; Ōmura S; Shiomi K
J Antibiot (Tokyo); 2017 May; 70(5):562-567. PubMed ID: 28293038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
